Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma

Insights into Imaging

Table 5 Quantitative assessment of initial human data across all sites (same cohort as for Table 4): measurements of ADC values of the bladder fluid

Site	Protocol	Subject	Gender	Age	Disease status	ADC (20cm²ROI within the bladder)
Site	Protocol	Subject	Gender	Years	Disease status	Mean	st dev	% relative difference
1	A	p	m	56	Untreated	326	16	5
2	A	p	m	64	Treated	333	22	8
3	B	p	m	68	Untreated	285	15	− 8
4	A	p	m	59	Untreated	311	18	1
5	C	v	f	31	Healthy volunteer	375	19	21
6	D	p*	m	72	Unknown	295	18	− 4
7	A	p	m	45	Untreated	295	20	− 4
8	C	v	f	29	Healthy volunteer	na	na	na
9	A	p	m	71	Untreated	292	17	− 6
10	C	v	m	20	Healthy volunteer	327	14	6
11	A	p	f	55	Treated	271	29	− 12
12	A	p	m	66	Untreated	286	24	− 7
Cohort mean values				53		309	19	0

Demographics (gender, age and disease status) for each subject is included. The relative difference was measured against the mean cohort ADC value
p = patient; v = volunteer; p* = non-trial patient
m = male; f = female
na = not available
treated = 3 months post-ASCT (autologous stem cel transplantation)
ADC = apparent diffusion coefficient; units of 10^-5mm²/s; ROI = region of interest